CD34 and acute myeloid leukemia: When myeloblasts are identified by an experienced hematopathologist, ERG highlights them in the majority of cases (16/17), demonstrating that ERG has a higher sensitivity than the commonly used IHC markers for AML, CD34, and CD117.